Our current findings implicate UNC13B as a functionally important node in multiple myeloma, and thus provide a conceptual foundation for future therapeutic development—both in terms of designing UNC13B-specific inhibitors and exploring synergistic strategies that disrupt exocytosis and cell survival. This evidence concerns the gene UNC13B and plasma cell myeloma.